Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In AlloVir To Contact Him Directly To Discuss Their Options
If you suffered significant losses in AlloVir stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/ALVR.
There is no cost or obligation to you.
New York, New York--(Newsfile Corp. - January 16, 2024) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against AlloVir, Inc. ("AlloVir" or the "Company") (NASDAQ: ALVR).
Faruqi & Faruqi is a leading minority and Woman-owned national securities law firm with offices in New York, Pennsylvania, California and Georgia.
On December 22, 2023, AlloVir announced that it was discontinuing three Phase 3 studies testing the Company's T cell therapy posoleucel for the prevention of certain viruses in immunocompromised people over efficacy concerns and stated that it would explore strategic alternatives for the Company. Specifically, AlloVir said it was discontinuing the studies after pre-planned analyses concluded they wouldn't meet their primary endpoints.
On this news, AlloVir's stock price fell sharply during intraday trading on December 22, 2023.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/194440
